603566.SH
普莱柯
SSE · Healthcare · Biotechnology · CN
CNY 10.22
−0.68%Aug 24, 2026, 09:01 UTC
Pulike Biological Engineering announced its H1 2026 results with revenue of 491 million yuan, down 12.18% year-on-year, and net profit attributable to shareholders of 77.32 million yuan, down 33.45% year-on-year.
Source:Jul 21, 2026, 09:03 UTC
Pulike's controlled subsidiary Zhongpu Biological Pharmaceutical Co., Ltd. received veterinary drug product approval numbers from the Ministry of Agriculture and Rural Affairs for two foot-and-mouth disease vaccines, enabling production.